Biogen has launched 'LEQEMBI®' (Lecanemab) for Alzheimer's Disease treatment in China. Additionally, Biogen's 'TOFIDENCE' (tocilizumab) has been approved in the EU. Lecanemab shows promise in slowing cognitive decline by targeting brain plaque.
A new Alzheimer's drug, Lecanemab, targets brain plaque, showing promise in slowing cognitive decline. https://t.co/fmS7FGRmZD
Biogen’s TOFIDENCE (tocilizumab) Approved in the EU https://t.co/pSkQuxI99a | by @goodwinlaw
Where the future of Alzheimer's drugs is heading https://t.co/4o8orKfL72 by @caitlinnowens
$BIIB LEQEMBI for the Treatment of Alzheimer’s Disease Launched in China. https://t.co/2sGAM8w4Ol
“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China $BIIB https://t.co/2SM2XXTPfw